Introduction {#s1}
============

Cancer is a complex disease that results from interactions between multiple genetic and environmental factors \[[@B1]-[@B3]\]. A characteristic of cancer is genetic instability, which can be caused by transgenation and acquired aneuploidy \[[@B4]\]. Genetic instability mostly occurs at the chromosomal level, including losses and gains of whole or large portions of chromosomes \[[@B5]\]. Chromosomal segregation is accomplished by the mitotic spindle, which links whole chromosomes to opposite poles of the cell, and segregates the duplicated DNA equally into two daughter cells \[[@B6]\]. In mammalian cells, centrosomes are the major microtubule organizing centers (MTOC) and play a vital role in symmetrical mitotic spindle formation and mitosis. Serine/threonine kinase 15 (STK15), a centrosome**-**localized serine/threonine kinase, acts as a critical regulator of mitotic centrosome maturation and spindle assembly. It has a particular role in G2 to M phase, primarily through its phosphorylation functions, and plays an important role in the development and progression of cancer malignancy \[[@B7]\].

A non-synonymous single nucleotide polymorphism (SNP) of *STK15*, the F31I polymorphism (rs2273535), has been identified in the coding region of *STK15*. The *STK15* F31I polymorphism (91 T→A), a SNP in exon 3 of *STK15*, encodes a phenylalanine→isoleucine substitution at amino acid residue 31 (F31I) \[[@B8]\]. In recent years, the F31I polymorphism has been intensely investigated for its association with the risk of multiple cancers. Many studies have indicated that the *STK15* F31I polymorphism is a general low penetrance susceptibility gene in a number of cancers, particularly breast, colorectal, and esophageal cancer \[[@B9]-[@B11]\]. However, results from these studies remain inconsistent, perhaps due to small sample size limitations, ethnic diversity in allele frequencies, and publication bias. Therefore, to confirm the role of the *STK15* F31I polymorphism in tumorigenesis, we conducted a comprehensive meta-analysis on eligible case-control studies published to date. To the best of our knowledge, this is the most comprehensive meta-analysis regarding the *STK15* F31I polymorphism and its association with cancer risk.

Materials and Methods {#s2}
=====================

This meta-analysis is reported according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guideline ([Table **S1**](#pone.0082790.s001){ref-type="supplementary-material"}. PRISMA checklist) \[[@B12]\].

Search Strategy {#s2.1}
---------------

Genetic association articles published on cancer and the *STK15* F31I polymorphism, up to May 29, 2013, were investigated by searching PubMed, EMBASE, CBM (Chinese BioMedical Disc) and CNKI (Chinese National Knowledge Infrastructure) with combinations of the following terms: \"stk15\", \"Aurora-A\", \"BTAK\", \"AIKI\", \"polymorphism\", \"SNP\", \"mutation\", \"carcinoma\", \"cancer\", \"neoplasm\", and \"malignance\". In addition, the publication language was restricted to English and Chinese. All bibliographies listed in these studies and published reviews were checked for original and relevant studies.

Inclusion and Exclusion Criteria {#s2.2}
--------------------------------

Eligible studies had to meet the following criteria: 1) evaluated the *STK15* F31I polymorphism and cancer risk, 2) designed as a case-control study, 3) provided data on genotype or allele frequency in case groups and control groups, 4) provided the genotyping method and ethnicity, and 5) control genotype distributions consistent with Hardy-Weinberg equilibrium (HWE). Exclusion criteria included the following: 1) overlapping data, 2) not case-control studies, and 3) review publication.

Data Extraction {#s2.3}
---------------

Information from all eligible publications was carefully and independently extracted through three reviewers (W. Tang, H. Qiu, and H. Ding). In case of conflicting evaluations, differences were resolved by further discussion among all reviewers. For each included study the following data was extracted: first author, cancer type, year of publication, country, ethnicity of study subjects, number of cases and controls, genotype method, allele and genotype frequency, and HWE in controls.

Statistical Analysis {#s2.4}
--------------------

Deviation from the HWE among the controls was evaluated for each single study using an internet-based HWE calculator (http://ihg.gsf.de/cgi-bin/hw/hwa1.pl). The crude odds ratio (OR) with the corresponding 95% confidence intervals (95% CI) was used to measure the strength of the association between the *STK15* F31I polymorphism and cancer risk. The significance of the pooled OR was assessed using the Z-test and *P*-value (two-tailed), and *P*\<0.05 was considered statistically significant. In our study, a Chi-square-based I^2^ test was used to check potential heterogeneity among studies; I^2^\<25% indicated low heterogeneity, 25%≤I^2^≤50% indicated moderate heterogeneity, and I^2^\>50% indicated large heterogeneity \[[@B13]\]. The heterogeneity was considered statistically significant at I^2^\>50% or *P*\<0.10. If heterogeneity existed, the pooled ORs were calculated according to the random-effects model (the DerSimonian--Laird method) or the fixed-effects model was used (the Mantel--Haenszel method). Subgroup analyses were conducted according to ethnicity and cancer type to measure ethnicity-specific and cancer type-specific effects (any cancer type evaluated by less than three individual case-control studies was combined into \"other cancers\"). Sensitivity analysis was also carried out to determine whether any excluded studies affected the stability of our results. Galbraith radial plot and further stratified analyses were used to analyze the source the heterogeneity. In our studies, the funnel plot and Egger's test were used to assess potential publication bias, which was measured by visual inspection of an asymmetric plot. In addition, for the interpretation of Egger's test, statistical significance was defined as *P*\<0.05. Statistical analyses were performed using STATA (v12.0) statistical software.

Results {#s3}
=======

Characteristics {#s3.1}
---------------

After an initial search, a total of 151 published articles relevant to the topic were identified from databases (PubMed, Embase, CBM and CNKI). With additional filters, 120 of these articles were excluded (26 for duplication of titles, 10 for not being case**-**control studies, five for an association with cancer treatment, 72 for irrelevance to gene polymorphisms and cancer, six reviews and one case-control study for overlapping data). After this step, 31 qualified and original papers fit the inclusion criteria. After a manual search of the bibliography lists from retrieved articles, another two articles were included ([Figure **1**](#pone-0082790-g001){ref-type="fig"}). Afterwards, six case-control studies were excluded because the number of genotypes in the control group statistically deviated from HWE. Overall, 27 total case-control studies on the association between the *STK15* F31I polymorphism and cancer risk were recruited in this meta-analysis. Among the 27 case-control studies, ten investigated breast cancer \[[@B8],[@B9],[@B14]-[@B21]\], four investigated colorectal cancer \[[@B10],[@B22]-[@B24]\], and three investigated esophageal cancer \[[@B11],[@B25],[@B26]\]. The other studies investigated gastric cancer, lung cancer, renal cell carcinoma, bladder cancer, glioblastoma, hepatocellular carcinoma, and ovarian cancer \[[@B27]-[@B36]\]. As for subjects in these studies, 11 were Asian \[[@B9],[@B11],[@B19]-[@B21],[@B23],[@B25]-[@B29]\] and 16 were Caucasian \[[@B8],[@B10],[@B14]-[@B18],[@B22],[@B24],[@B30]-[@B36]\]. Characteristics of populations and cancer types in each individual study recruited in the meta-analysis are listed in [Table **1**](#pone-0082790-t001){ref-type="table"}. The distribution of the *STK15* F31I polymorphism and allele among patients and controls is listed in [Table **2**](#pone-0082790-t002){ref-type="table"}. Results of the meta-analysis from different comparative genetic models are summarized in [Table **3**, Table **4**, and Table **5**](#pone-0082790-t003){ref-type="table"}.

![Flow diagram of articles selection process for *STK15* F31I polymorphism and cancer risk meta-analysis.](pone.0082790.g001){#pone-0082790-g001}

10.1371/journal.pone.0082790.t001

###### Characteristics of populations and cancer types of the individual studies included in the meta-analysis.

  Study                  Year   Ethnicity    Country          Cancer type                Sample size (case/control)   Genotype method
  ---------------------- ------ ------------ ---------------- -------------------------- ---------------------------- ----------------------------
  Sang et al.            2012   Asians       China            esopheal cancer            380/380                      MALDI-TOF MS
  Ruan et al.            2011   Asians       China            breast cancer              1334/1568                    TaqMan
  Navaratne et al.       2010   Caucasians   USA              glioblastoma               96/93                        PCR-RFLP
  Akkiz et al.           2010   Caucasians   Turkey           hepatocellular carcinoma   128/128                      PCR-RFLP
  Song et al.            2010   Asians       China            bladder cancer             60/60                        PCR-RFLP
  Chen et al.            2009   Asians       China            esopheal cancer            188/324                      PCR-RFLP
  MARIE-GENICA           2009   Caucasians   German           breast cancer              3136/5466                    MALDI-TOF MS
  Ricketts et al.        2009   Caucasians   Polish           renal cell carcinoma       328/311                      MLPA
  Dogan et al.           2008   Caucasians   Turkey           lung Cancer                102/102                      Direct sequencing
  Chen et al.            2007   Caucasians   USA              colorectal cancer          60/65                        Direct sequencing
  Wang et al.            2007   Caucasians   USA              lung cancer                1518/1518                    TaqMan
  Vidarsdottir et al.    2007   Caucasians   Iceland          breast cancer              759/653                      TaqMan
  Tchatchou et al.       2007   Caucasians   German           breast cancer              727/819                      TaqMan
  Hammerschmied et al.   2007   Caucasians   German;USA       renal cell carcinoma       156/158                      PCR-RFLP
  Webb et al.            2006   Caucasians   UK               colorectal cancer          2558/2680                    Illuminasentric bead array
  Fletcher et al.        2006   Caucasians   UK               breast cancer              507/875                      PCR-RFLP
  Zhang et al.           2006   Asians       China            colorectal cancer          283/283                      PCR-RFLP
  Cox. et al.            2006   Caucasians   USA              breast cancer              1259/1742                    TaqMan
  Ju et al.              2006   Asians       Korea            gastric cancer             501/427                      MALDI-TOF MS
  Chen et al.            2005   Asians       China            gastric cancer             68/75                        PCR-RFLP
  Hienonen et al.        2005   Caucasians   Finland          colorectal cancer          235/94                       Direct sequencing
  Lo et al.              2005   Asians       China(Taiwan)    breast cancer              709/1972                     TaqMan
  DiCioccio et al.       2004   Caucasians   UK;Denmark;USA   ovarian Cancer             1821/2467                    TaqMan
  Sun et al.             2004   Asians       China            breast cancer              520/520                      PCR-RFLP
  Egan et al.            2004   Caucasians   USA              breast cancer              940/830                      Direct sequencing
  Miao et al.            2004   Asians       China            esopheal cancer            656/656                      PCR-RFLP
  Dai et al.             2004   Asians       China            breast cancer              1193/1310                    TaqMan

MALDI--TOF MS: Matrix-Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry

PCR-RFLP: polymerase chain reaction-restriction fragment length polymorphism

MLPA: Multiplex Ligation Dependent Probe Amplification

10.1371/journal.pone.0082790.t002

###### Distribution of *stk15* *F31I* polymorphisms genotype and allele among multiple cancer patients and controls.

                         Case   Control   Case   Control   HWE                                       
  ---------------------- ------ --------- ------ --------- ------ ------ ------ ------ ------ ------ -----
  Sang et al.            46     161       173    39        188    153    253    507    266    494    Yes
  Ruan et al.            167    568       599    161       691    716    902    1766   1013   2123   Yes
  Navaratne et al.       4      33        59     6         33     54     41     151    45     141    Yes
  Akkiz et al.           4      47        77     2         27     99     55     201    31     225    Yes
  Song et al.            33     15        12     18        25     17     81     39     61     59     Yes
  Chen et al.            66     79        43     118       168    38     211    165    404    244    Yes
  MARIE-GENICA           167    1096      1873   249       1927   3290   1430   4842   2425   8507   Yes
  Ricketts et al.        207    105       16     171       122    18     519    137    464    158    Yes
  Dogan et al.           6      38        58     3         40     59     50     154    46     158    Yes
  Chen et al.            3      13        44     6         21     38     19     101    33     97     Yes
  Wang et al.            36     373       692    51        320    594    445    1757   422    1508   Yes
  Vidarsdottir et al.    42     288       429    21        231    401    372    1146   273    1033   Yes
  Tchatchou et al.       433    257       37     485       287    47     1123   331    1257   381    Yes
  Hammerschmied et al.   7      57        92     12        65     81     71     241    89     227    Yes
  Webb et al.            114    880       1564   125       888    1667   1108   4008   1138   4222   Yes
  Fletcher et al.        18     154       335    48        280    547    190    824    376    1374   Yes
  Zhang et al.           142    111       30     104       137    42     395    171    345    221    Yes
  Cox. et al.            66     401       774    65        571    1075   533    1949   701    2721   Yes
  Ju et al.              211    215       75     179       190    58     637    365    548    306    Yes
  Chen et al.            36     27        5      33        32     10     99     37     98     52     Yes
  Hienonen et al.        19     94        122    5         43     46     132    338    53     135    Yes
  Lo et al.              348    288       71     886       887    196    984    430    2659   1279   Yes
  DiCioccio et al.       71     502       821    99        649    1213   644    2144   847    3075   Yes
  Sun et al.             256    214       50     192       262    66     726    314    646    394    Yes
  Egan et al.            50     331       559    31        283    516    431    1449   345    1315   Yes
  Miao et al.            308    290       58     249       316    91     906    406    814    498    Yes
  Dai et al.             490    491       121    534       503    149    1471   733    1571   801    Yes

HWE: Hardy--Weinberg equilibrium.

10.1371/journal.pone.0082790.t003

###### Summary of results of the meta-analysis from different comparative genetic models in the subgroup analysis by ethnicity.

  Polymorphism   Genetic comparison   Population   OR(95%CI)             *P*         Test of heterogeneity   Model   
  -------------- -------------------- ------------ --------------------- ----------- ----------------------- ------- ---
                 AA+TA vs. TT         All          1.04(0.97-1.12)       0.265       0.002                   50.1%   R
                                      Asians       1.07(0.89-1.28)       0.482       0.001                   65.6%   R
                                      Caucasians   1.04(0.97-1.11)       0.305       0.084                   34.8%   R
                 AA vs. TA+TT         All          **1.18(1.06-1.31)**   **0.002**   0.000                   56.2%   R
                                      Asians       **1.27(1.10-1.47)**   **0.001**   0.002                   64.8%   R
                                      Caucasians   1.08(0.93-1.26)       0.310       0.026                   45.3%   R
                 AA vs. TT            All          **1.16(1.01-1.32)**   **0.035**   0.000                   55.7%   R
                                      Asians       **1.26(1.01-1.56)**   **0.039**   0.001                   66.5%   R
  *STK15* F31I                        Caucasians   1.08(0.91-1.28)       0.388       0.031                   43.9%   R
                 TA vs. TT            All          1.01(0.95-1.08)       0.745       0.028                   37.2%   R
                                      Asians       0.96(0.81-1.13)       0.628       0.015                   54.6%   R
                                      Caucasians   1.03(0.98-1.08)       0.224       0.247                   18.0%   F
                 AA vs. TA            All          **1.18(1.06-1.30)**   **0.001**   0.003                   48.4%   R
                                      Asians       **1.28(1.12-1.47)**   **0.000**   0.010                   57.0%   R
                                      Caucasians   1.07(0.93-1.23)       0.342       0.081                   35.2%   R
                 A vs. T              All          **1.08(1.01-1.14)**   **0.015**   0.000                   64.4%   R
                                      Asians       **1.14(1.02-1.28)**   **0.023**   0.000                   73.9%   R
                                      Caucasians   1.04(0.97-1.11)       0.252       0.010                   50.9%   R

F indicates fixed model; R indicates random model

10.1371/journal.pone.0082790.t004

###### Summary of results of the meta-analysis from different comparative genetic models in the subgroup analysis by cancer type.

  Polymorphism   Genetic comparison   Cancer type         OR(95%CI)             *P*         Test of heterogeneity   Model   
  -------------- -------------------- ------------------- --------------------- ----------- ----------------------- ------- ---
                 AA+TA vs. TT         All                 1.04(0.97-1.12)       0.265       0.002,                  50.1%   R
                                      Breast cancer       1.05(0.99-1.10);      0.120       0.462                   0.0%    F
                                      Colorectal cancer   1.04(0.94-1.15)       0.479       0.130                   46.9%   F
                                      Esophageal cancer   0.86(0.44-1.68)       0.652       0.000                   90.2%   R
                                      Others              1.07(0.90-1.26)       0.445       0.007                   43.2%   R
                 AA vs. TA+TT         All                 **1.18(1.06-1.31)**   **0.002**   0.000                   56.2%   R
                                      Breast cancer       **1.20(1.05-1.37)**   **0.007**   0.005                   61.5%   R
                                      Colorectal cancer   1.21(0.76-1.93)       0.416       0.027                   67.4%   R
                                      Esophageal cancer   **1.28(1.08-1.53)**   **0.005**   0.151                   47.1%   F
                                      Others              1.10(0.84-1.44)       0.468       0.015                   56.3%   R
                 AA vs. TT            All                 **1.16(1.01-1.32)**   **0.035**   0.000                   55.7%   R
                                      Breast cancer       **1.22(1.10-1.35**)   **0.000**   0.131                   34.6%   F
                                      Colorectal cancer   1.18(0.72-1.94)       0.501       0.078                   56.1%   R
  *STK15* F31I                        Esophageal cancer   1.02(0.47-2.22)       0.963       0.000                   88.6%   R
                                      Others              1.04(0.77-1.41)       0.794       0.065                   44.1%   R
                 TA vs. TT            All                 1.01(0.95-1.08)       0.745       0.028                   37.2%   R
                                      Breast cancer       1.01(0.96-1.07)       0.667       0.752                   0.0%    F
                                      Colorectal cancer   1.03(0.93-1.15)       0.553       0.313                   15.7%   F
                                      Esophageal cancer   0.78(0.42-1.47)       0.448       0.000                   87.5%   R
                                      Others              1.05(0.94-1.16)       0.392       0.664                   0.0%    F
                 AA vs. TA            All                 **1.18(1.06-1.30)**   **0.001**   0.003                   48.4%   R
                                      Breast cancer       **1.19(1.04-1.36)**   **0.011**   0.011                   57.8%   R
                                      Colorectal cancer   1.25(0.80-1.95)       0.335       0.050                   61.7%   R
                                      Esophageal cancer   **1.32(1.10-1.58)**   **0.003**   0.853                   0.0%    F
                                      Others              1.07(0.83-1.39)       0.591       0.039                   49.0%   R
                 A vs. T              All                 **1.08(1.01-1.14)**   **0.015**   0.000                   64.4%   R
                                      Breast cancer       **1.08(1.01-1.15)**   **0.017**   0.025                   52.8%   R
                                      Colorectal cancer   1.05(0.80-1.38)       0.732       0.008                   74.7%   R
                                      Esophageal cancer   1.00(0.71-1.42)       0.986       0.000                   87.9%   R
                                      Others              1.11(0.95-1.28)       0.180       0.003                   64.5%   R

F indicates fixed model; R indicates random model

10.1371/journal.pone.0082790.t005

###### Summary of results of the meta-analysis from different comparative genetic models in the breast cancer subgroup analysis by ethnicity.

  Polymorphism   Genetic comparison   Population   OR(95%CI)             *P*         Test of heterogeneity   Model   
  -------------- -------------------- ------------ --------------------- ----------- ----------------------- ------- ---
                 AA+TA vs. TT         All          1.05(0.99-1.10)       0.120       0.462                   0.0%    F
                                      Asians       1.07(0.96-1.20)       0.211       0.482                   0.0%    F
                                      Caucasians   1.04(0.97-1.10)       0.284       0.309                   16.3%   F
                 AA vs. TA+TT         All          **1.20(1.05-1.37)**   **0.007**   0.005                   61.5%   R
                                      Asians       **1.23(1.00-1.50)**   **0.049**   0.006                   75.9%   R
                                      Caucasians   1.18(0.96-1.44)       0.109       0.055                   53.7%   R
                 AA vs. TT            All          **1.22(1.10-1.35)**   **0.000**   0.131                   34.6%   F
                                      Asians       **1.21(1.01-1.45)**   **0.037**   0.266                   24.3%   F
  *STK15* F31I                        Caucasians   1.23(0.98-1.54)       0.075       0.081                   49.0%   R
                 TA vs. TT            All          1.01(0.96-1.07)       0.667       0.752                   0.0%    F
                                      Asians       1.02(0.90-1.14)       0.804       0.492                   0.0%    F
                                      Caucasians   1.01(0.95-1.08)       0.723       0.628                   0.0%    F
                 AA vs. TA            All          **1.19(1.04-1.36)**   **0.011**   0.011                   57.8%   R
                                      Asians       1.22(0.98-1.52)       0.074       0.005                   76.6%   R
                                      Caucasians   **1.14(1.00-1.29)**   **0.042**   0.136                   40.5%   F
                 A vs. T              All          **1.08(1.01-1.15)**   **0.017**   0.025                   52.8%   R
                                      Asians       1.15(0.97-1.36)       0.098       0.034                   65.5%   R
                                      Caucasians   1.05(1.00-1.10)       0.069       0.109                   44.5%   F

F indicates fixed model; R indicates random model

Quantitative Synthesis {#s3.2}
----------------------

In total, 19,267 multiple cancer cases and 24,359 controls from 27 eligible and original case--control studies were recruited for meta-analysis of the association between the *STK15* F31I polymorphism and cancer risk. Divided by ethnicity, 11 case-control studies were focused on Asian subjects and 16 case-control studies focused on Caucasian subjects. After combining all qualified studies, there was statistical evidence of an association between the *STK15* F31I polymorphism and increased overall cancer risk in four genetic models: AA vs. TA+TT (OR, 1.18; 95% CI, 1.06--1.31; *P*=0.002), AA vs. TT (OR, 1.16; 95% CI, 1.01--1.32; *P*=0.035), AA vs. TA (OR, 1.18; 95% CI, 1.06--1.30; *P*=0.001), and A vs. T (OR, 1.08; 95% CI, 1.01--1.14; *P*=0.015) ([Table **3**](#pone-0082790-t003){ref-type="table"}, [Figure **2**](#pone-0082790-g002){ref-type="fig"}). In a stratified analysis by cancer type, there was an increased risk of breast cancer in four genetic models: AA vs. TA+TT (OR, 1.20; 95% CI, 1.05--1.37; *P*=0.007), AA vs. TT (OR, 1.22; 95% CI, 1.10--1.35; *P*=0.000), AA vs. TA (OR, 1.19; 95% CI, 1.04--1.36; *P*=0.011), and A vs. T (OR, 1.08; 95% CI, 1.01--1.15; *P*=0.017) and of esophageal cancer in two genetic model: AA vs. TA+TT (OR, 1.28; 95% CI, 1.08--1.53; *P*=0.005) and AA vs. TA (OR, 1.32; 95% CI, 1.10--1.58; *P*=0.003) ([Table **4**](#pone-0082790-t004){ref-type="table"}). In a stratified analysis by ethnicity, significant increases in cancer risk were observed for Asians, but not Caucasians, for four genetic models: AA vs. TA+TT (OR, 1.27; 95% CI, 1.10--1.47; *P*=0.001), AA vs. TT (OR, 1.26; 95% CI, 1.01--1.56; *P*=0.039), AA vs. TA (OR, 1.28; 95% CI, 1.12--1.47; *P*=0.000) and A vs. T (OR, 1.14; 95% CI, 1.02--1.28; *P*=0.023) ([Table **3**](#pone-0082790-t003){ref-type="table"}). In addition, in a stratified analysis by ethnicity in the breast cancer subgroup, significant increases in cancer risk were observed among Asians for two genetic models: AA vs. TA+TT (OR, 1.23; 95% CI, 1.00--1.50; *P*=0.049) and AA vs. TT (OR, 1.21; 95% CI, 1.01--1.45; *P*=0.037), as well as among Caucasians in one genetic model: AA vs. TA (OR, 1.14; 95% CI, 1.00--1.29; *P*=0.042) ([Table **5**](#pone-0082790-t005){ref-type="table"})**.**

![Meta-analysis with a random-effects model for the association between the risk of cancer and the *STK15* F31I polymorphism (A vs. T).](pone.0082790.g002){#pone-0082790-g002}

Tests for Publication Bias, Sensitivity Analyses, and Heterogeneity {#s3.3}
-------------------------------------------------------------------

In this meta-analysis, Begg's Funnel plot and Egger's test were both conducted to assess publication bias ([Figure **3**](#pone-0082790-g003){ref-type="fig"}). The shape of funnel plot showed the evidence of funnel plot symmetry in all the genetic model. The results indicated that there were no publication bias for overall cancer in current meta-analysis (A vs. T: Begg's test *P*=0.802, Egger's test *P*=0.553; AA vs. TT: Begg's test *P*=1.000, Egger's test *P*=0.938; TA vs. TT: Begg's test *P*=0.532, Egger's test *P*=0.509; AA+TA vs. TT: Begg's test *P*=0.900, Egger's test *P*=0.856; AA vs. TT+TA: Begg's test *P*=0.739, Egger's test *P*=0.784; AA vs. TA: Begg's test *P*=0.802, Egger's test *P*=0.585).

![Begg's funnel plot of meta-analysis of between the *STK15* F31I polymorphism and the risk of cancer in the dominant model.](pone.0082790.g003){#pone-0082790-g003}

Sensitivity analyses were conducted to evaluate the influence of each individual dataset on the pooled OR by deleting each particular dataset dropped at a time. The statistical significances of the overall results did not alter when any individual study was omitted, confirming the stability of the results ([Figure **4**](#pone-0082790-g004){ref-type="fig"}). Trim and fill method was also used to perform sensitivity analyses. The findings showed the results of this meta-analysis were reliable ([Figure **5**](#pone-0082790-g005){ref-type="fig"}).

![Sensitivity analysis of the influence of A vs. T in overall cancer meta-analysis (random--effects estimates).](pone.0082790.g004){#pone-0082790-g004}

![Filled funnel plot of meta-analysis of between the *STK15* F31I polymorphism and the risk of cancer in the dominant model.](pone.0082790.g005){#pone-0082790-g005}

The results showed there were large heterogeneities among the studies enrolled. Because tumor origin and ethnicity can influence the results from meta-analyses, we performed subgroup analyses by cancer type and ethnicity ([Table **3** and Table **4**](#pone-0082790-t003){ref-type="table"}).The results indicated that esophageal cancer, colorectal cancer, Asian population subgroup may contribute to the heterogeneity. As shown in [Table **3**](#pone-0082790-t003){ref-type="table"}, heterogeneity was significant in allele comparison. Galbraith radial plot also was used to analyze the heterogeneity in allele comparison ([Figure **6**](#pone-0082790-g006){ref-type="fig"}). The results identified eight outliers which might contribute to the major sources of heterogeneity. Further stratified meta-analysis suggested an association of studies published after 2006, conducted in Chinese population and small sample size design (≤1000 subjects) with more prominent heterogeneity (data not shown).

![Galbraith radial plot of meta-analysis (A vs. T compare genetic model).](pone.0082790.g006){#pone-0082790-g006}

Discussion {#s4}
==========

Accumulating evidence suggests environmental factors, genetic components, and gene--environment interactions play important roles in cancer development and progression \[[@B37]-[@B42]\]. Recently, a growing interest in the associations between genetic polymorphisms and cancer risk has led to increasing studies on tumor etiology. Many studies have linked tumor development and progression to the amplification and overexpression of *STK15* in multiple human cancers (such as breast cancer, colorectal cancer, esophageal cancer, as well as other types of cancer) \[[@B43]-[@B46]\]. The *STK15* F31I polymorphism has been extensively investigated, and many studies have examined the hypothesis that this polymorphism is relevant to the risk of a variety of cancers; however, the results remain inconclusive and ambiguous. Therefore, we conducted a comprehensive meta-analysis to assess the strength of the association between the *STK15* F31I polymorphism and overall cancer risk, and further performed a stratified analysis by ethnicity and cancer type. This meta-analysis, including 27 case-control studies, identified associations between *STK15* F31I polymorphism and cancer risk. *STK15* F31I polymorphisms (AA vs. TA+TT, AA vs. TT, AA vs. TA, and A vs. T) significantly increased overall cancer risk. In a stratified analysis by cancer type, *STK15* F31I polymorphisms (AA vs. TA+TT, AA vs. TT, AA vs. TA, and A vs. T) were also associated with a significant increase in breast cancer risk and esophageal cancer (AA vs. TA+TT and AA vs. TA). In a stratified analysis by ethnicity, the association of *STK15* F31I polymorphisms was significant in Asians but not Caucasians.

*STK15*, also named Aurora A, BTAK, and AIKI, encodes a serine/threonine kinase that acts as a crucial component in spindle formation, the centrosome maturation process, and proper cytokinesis during mitosis. It is located on chromosome 20q13, a region associated with a number of human cancers \[[@B47]\]. These threonine kinases belong to a family of mitotic kinases that maintain chromosomal stability through phosphorylation. Thus, any severe defects in *STK15*, such as mutations, would lead to drastic genomic instability and trigger apoptosis through cell cycle checkpoint surveillance \[[@B19],[@B48]\]. Consequently, a cell harboring a defective *STK15* may lead to cancer \[[@B19]\]. Our results demonstrate a significant statistical impact of *STK15* F31I polymorphism on cancer risk. The *STK15* F31I polymorphism (T→A), which leads to an amino acid residue substitution at codon 31 phenylalanine (Phe) to isoleucine (Ile), is associated with cellular transformation and dramatically increases chromosomal instability \[[@B49]\]. The *STK15* F31I polymorphism (T→A) variant changes the activity of the *STK15* box 1, leading to an obstruction in p53 binding and the decreased degradation of *STK15* \[[@B7]\]. The stabilized overexpression of *STK15* results in centrosome amplification, improper cytokinesis, chromosomal instability, and the promotion of tumorigenesis \[[@B7]\]. In this meta-analysis, our results demonstrate that the T→A change in *STK15* may lead to *STK15*-triggered elevation of cell centrosome proliferation, cell transformation, and dramatically increased chromosomal instability, which may increase the risk of multiple cancers.

Since the outcomes from meta-analysis can be affected by cancer origins, stratified analysis was conducted according to cancer type for the *STK15* F31I polymorphism. The results demonstrate that the *STK15* F31I polymorphism is associated with an increased risk of breast cancer and esophageal cancer, but not colorectal cancer and other cancers. However, all results should be interpreted with caution. For esophageal cancer, only three case-control studies were recruited in the current meta-analysis, which may restrict statistical power to detect a real influence or generate a fluctuated assessment, large heterogeneities among the studies enrolled in current meta-analysis should also be taken into consideration. More large scale studies are needed to verify these results. Stratified analysis was also performed regarding ethnicity for the *STK15* F31I polymorphism. The *STK15* F31I polymorphism is associated with the risk of cancer in Asians but not Caucasians. This meta-analysis confirmed the mutual effect of genetic diversity and variants in different populations to the risks of various cancers. In addition, cancer risk was affected by genetic and environmental factors on different levels. The possible reason of the conflicting findings among different ethnicities could be that different genetic backgrounds and environmental factors they exposed to may have disproportionate effects on cancer risk. In the future, further investigations with large sample sizes should be conducted to identify these associations, particularly with regard to gene--gene and gene--environment interactions.

Two significant issues should be addressed in this study, that is, heterogeneity and publication bias, which may influence the results of meta-analysis. We don't detect a significant publication bias in this meta-analysis, suggesting the reliability of our results. Significant heterogeneity was observed between publications for *STK15* F31I polymorphisms. Potential sources of heterogeneity include the publication year, ethnicity, country, cancer type, sample size, and so on. When subgroup analyses were carried out according to ethnicity and cancer type, this heterogeneity was greatly reduced or removed in some subgroups, implying different effects on cancer types and ethnic populations, even for the same polymorphism. And then we performed further subgroup analyses by publication year, country, and sample size. The pooled subgroup analysis of a subset of studies published after 2006, esophageal cancer, Asian population, studies conducted in Chinese population and small sample size, suggested an association with more prominent heterogeneity. The reason might be due to uncontrolled mixed factors, the various susceptibility of cancer in different race or to internal bias in the study design. It is certain that the design of some of the included studies was suboptimal in this meta-analysis. From the forest plot in A vs. T compare genetic model ([Figure **2**](#pone-0082790-g002){ref-type="fig"}), one can identify that 8 studies are the main sources of heterogeneity \[[@B11],[@B21]-[@B23],[@B25],[@B27],[@B33],[@B36]\]. In some publications, the study design included considerable oversights, for example, some investigations used small sample sizes (≤1000 subjects) \[[@B22],[@B23],[@B25],[@B27],[@B33],[@B36]\]. Publication year may be the source of heterogeneity. Some studies published after 2006 was identified with prominent heterogeneity \[[@B22],[@B25],[@B27],[@B33],[@B36]\]. When come to country origins, studies conducted in Chinese population contribute the major outlier \[[@B11],[@B21],[@B23],[@B25],[@B27]\].

The power of this meta-analysis (α=0.05) was evaluated for each single genetic model using an internet-based Power and Sample Size Calculator (PS, version 3.0, 2009, http://biostat.mc.vanderbilt.edu/twiki/bin/view/Main/PowerSampleSize). The power was 1.000 in four genetic models (AA vs. TA+TT, AA vs. TT, AA vs. TA, and A vs. T), 0.526 in AA+TA vs. TT genetic model, and 0.075 in TA vs. TT genetic model.

However, there are certain limitations in this study that should be acknowledged. First, large heterogeneity exists in our meta-analysis, which means the results should be interpreted with caution. Second, all recruited case--control studies were from Asians and Caucasians; thus, our results may only be suitable for these populations. Third, only published studies were eligible in this meta-analysis; therefore, some relevant unpublished studies were inevitably missed, which may lead to bias. Fourth, due to the lack of sufficient and uniform information in original case-control studies, data were not stratified by other factors (e.g., age, smoking, alcohol consumption, and other lifestyle factors). Considering the complexity of cancer etiology and the low penetrance cancer susceptibility gene effects from *STK15* F31I SNP, these important environmental factors should not be ignored.

In summary, this meta-analysis suggests the *STK15* F31I polymorphism represents a low risk factor for cancer, especially in Asians, in breast cancer and esophageal cancer subgroup. In the future, more studies with large sample sizes should be carried out to clarify the association between *STK15* F31I polymorphism and cancer risk, especially for gene--gene and gene--environment interactions.
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